Literature DB >> 21263052

Penetration of topically administered 0.5-percent caspofungin eye drops into human aqueous humor.

Chin Fen Neoh1, Lok Leung, Anant Misra, Rasik B Vajpayee, Geoffrey E Davies, Robert O Fullinfaw, Kay Stewart, David C M Kong.   

Abstract

Ten participants attending elective anterior segment eye surgery received 0.5% caspofungin eye drops either 1 drop hourly for 4 h or 1 drop an hour before surgery. The eye drops were generally well tolerated. In the absence of inflammation or corneal abrasion, topical caspofungin does not achieve clinically relevant concentrations.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21263052      PMCID: PMC3067136          DOI: 10.1128/AAC.01175-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

1.  The protein distribution of bovine, human and rabbit aqueous humour and the difference in composition before and after disruption of the blood/aqueous humour barrier.

Authors:  J Bours
Journal:  Lens Eye Toxic Res       Date:  1990

2.  Candida glabrata endophthalmitis treated successfully with caspofungin.

Authors:  Juan C Sarria; Jay C Bradley; Ranya Habash; Kelly T Mitchell; Robert C Kimbrough; Ana M Vidal
Journal:  Clin Infect Dis       Date:  2005-02-01       Impact factor: 9.079

Review 3.  Pharmacotherapy of fungal eye infections.

Authors:  B Manzouri; G C Vafidis; R K Wyse
Journal:  Expert Opin Pharmacother       Date:  2001-11       Impact factor: 3.889

4.  Subtherapeutic ocular penetration of caspofungin and associated treatment failure in Candida albicans endophthalmitis.

Authors:  G M Gauthier; T M Nork; R Prince; D Andes
Journal:  Clin Infect Dis       Date:  2005-06-28       Impact factor: 9.079

5.  Management of endogenous fungal endophthalmitis with voriconazole and caspofungin.

Authors:  Sean M Breit; Seenu M Hariprasad; William F Mieler; Gaurav K Shah; Michael D Mills; M Gilbert Grand
Journal:  Am J Ophthalmol       Date:  2005-01       Impact factor: 5.258

6.  Topical caspofungin for treatment of keratitis caused by Candida albicans in a rabbit model.

Authors:  David Goldblum; Beatrice E Frueh; Gian-Marco Sarra; Konstantinos Katsoulis; Stefan Zimmerli
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

7.  Successful treatment of Fusarium endophthalmitis with voriconazole and Aspergillus endophthalmitis with voriconazole plus caspofungin.

Authors:  Marlene L Durand; Ivana K Kim; Donald J D'Amico; John I Loewenstein; Ellis H Tobin; Shalom J Kieval; Stephen S Martin; Dimitri T Azar; Frederick S Miller; Brandon J Lujan; Joan W Miller
Journal:  Am J Ophthalmol       Date:  2005-09       Impact factor: 5.258

8.  Intraocular caspofungin: in vitro safety profile for human ocular cells.

Authors:  M Kernt; A Kampik
Journal:  Mycoses       Date:  2010-02-19       Impact factor: 4.377

Review 9.  Fungal keratitis.

Authors:  M Srinivasan
Journal:  Curr Opin Ophthalmol       Date:  2004-08       Impact factor: 3.761

10.  Stability of cefazolin sodium eye drops.

Authors:  T H How; W Y Loo; K L Yow; L Y Lim; E W Chan; P C Ho; S Y Chan
Journal:  J Clin Pharm Ther       Date:  1998-02       Impact factor: 2.512

View more
  2 in total

1.  Stability of extemporaneously prepared 0.5-percent caspofungin eye drops: a potential cost-savings exercise.

Authors:  Chin Fen Neoh; Jovan Jacob; Lok Leung; Jian Li; Angela Stathopoulos; Kay Stewart; David C M Kong
Journal:  Antimicrob Agents Chemother       Date:  2012-04-02       Impact factor: 5.191

2.  New Formulations Loading Caspofungin for Topical Therapy of Vulvovaginal Candidiasis.

Authors:  Noelia Pérez-González; Nuria Bozal-de Febrer; Ana C Calpena-Campmany; Anna Nardi-Ricart; María J Rodríguez-Lagunas; José A Morales-Molina; José L Soriano-Ruiz; Francisco Fernández-Campos; Beatriz Clares-Naveros
Journal:  Gels       Date:  2021-12-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.